Lifeward (LFWD) Competitors

Lifeward logo
$2.95 -0.25 (-7.81%)
Closing price 11/19/2026 03:59 PM Eastern
Extended Trading
$2.93 -0.02 (-0.71%)
As of 05:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LFWD vs. CNXU, HSAQ, RNXT, LNSR, and POCI

Should you buy Lifeward stock or one of its competitors? Lifeward's main competitors and comparable companies include Conexeu Sciences (CNXU), Health Sciences Acquisitions Co. 2 (HSAQ), RenovoRx (RNXT), LENSAR (LNSR), and Precision Optics (POCI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Lifeward compare to Conexeu Sciences?

Lifeward (NASDAQ:LFWD) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Conexeu Sciences has lower revenue, but higher earnings than Lifeward. Conexeu Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifeward$22.03M0.38-$19.91M-$15.74N/A
Conexeu SciencesN/AN/A-$3.92M-$0.40N/A

Lifeward presently has a consensus target price of $8.00, indicating a potential upside of 171.19%. Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 861.54%. Given Conexeu Sciences' higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Lifeward.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Conexeu Sciences
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Conexeu Sciences had 1 more articles in the media than Lifeward. MarketBeat recorded 7 mentions for Conexeu Sciences and 6 mentions for Lifeward. Conexeu Sciences' average media sentiment score of 0.42 beat Lifeward's score of -0.51 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifeward
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Conexeu Sciences
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

26.8% of Lifeward shares are owned by institutional investors. 1.1% of Lifeward shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Conexeu Sciences has a net margin of 0.00% compared to Lifeward's net margin of -155.37%. Conexeu Sciences' return on equity of -200.20% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifeward-155.37% -295.75% -82.97%
Conexeu Sciences N/A -200.20%-177.26%

Summary

Conexeu Sciences beats Lifeward on 7 of the 13 factors compared between the two stocks.

How does Lifeward compare to Health Sciences Acquisitions Co. 2?

Lifeward (NASDAQ:LFWD) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Lifeward's net margin of -155.37%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifeward-155.37% -295.75% -82.97%
Health Sciences Acquisitions Co. 2 N/A N/A -2.38%

Lifeward presently has a consensus price target of $8.00, indicating a potential upside of 171.19%. Given Lifeward's stronger consensus rating and higher probable upside, research analysts clearly believe Lifeward is more favorable than Health Sciences Acquisitions Co. 2.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Health Sciences Acquisitions Co. 2
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Lifeward had 6 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 6 mentions for Lifeward and 0 mentions for Health Sciences Acquisitions Co. 2. Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 beat Lifeward's score of -0.51 indicating that Health Sciences Acquisitions Co. 2 is being referred to more favorably in the news media.

Company Overall Sentiment
Lifeward Negative
Health Sciences Acquisitions Co. 2 Neutral

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Lifeward.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifeward$22.03M0.38-$19.91M-$15.74N/A
Health Sciences Acquisitions Co. 2N/AN/A-$380KN/AN/A

26.8% of Lifeward shares are held by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. 1.1% of Lifeward shares are held by company insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lifeward has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its share price is 91% less volatile than the broader market.

Summary

Health Sciences Acquisitions Co. 2 beats Lifeward on 7 of the 13 factors compared between the two stocks.

How does Lifeward compare to RenovoRx?

RenovoRx (NASDAQ:RNXT) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Lifeward has a net margin of -155.37% compared to RenovoRx's net margin of -469.02%. RenovoRx's return on equity of -133.49% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
RenovoRx-469.02% -133.49% -101.50%
Lifeward -155.37%-295.75%-82.97%

RenovoRx currently has a consensus target price of $8.50, indicating a potential upside of 709.52%. Lifeward has a consensus target price of $8.00, indicating a potential upside of 171.19%. Given RenovoRx's stronger consensus rating and higher probable upside, equities research analysts clearly believe RenovoRx is more favorable than Lifeward.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RenovoRx
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.75
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 1.1% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, RenovoRx and RenovoRx both had 6 articles in the media. RenovoRx's average media sentiment score of 0.44 beat Lifeward's score of -0.51 indicating that RenovoRx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
RenovoRx
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lifeward
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

RenovoRx has a beta of 1.12, meaning that its stock price is 12% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

RenovoRx has higher earnings, but lower revenue than Lifeward. RenovoRx is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
RenovoRx$1.12M45.23-$11.17M-$0.31N/A
Lifeward$22.03M0.38-$19.91M-$15.74N/A

Summary

RenovoRx beats Lifeward on 10 of the 14 factors compared between the two stocks.

How does Lifeward compare to LENSAR?

LENSAR (NASDAQ:LNSR) and Lifeward (NASDAQ:LFWD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, media sentiment, institutional ownership, risk and earnings.

LENSAR has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

LENSAR has a net margin of 56.07% compared to Lifeward's net margin of -155.37%. LENSAR's return on equity of 1,254.25% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
LENSAR56.07% 1,254.25% 49.13%
Lifeward -155.37%-295.75%-82.97%

Lifeward has lower revenue, but higher earnings than LENSAR. LENSAR is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LENSAR$58.44M0.98-$34.28M-$0.40N/A
Lifeward$22.03M0.38-$19.91M-$15.74N/A

LENSAR presently has a consensus price target of $11.00, suggesting a potential upside of 137.07%. Lifeward has a consensus price target of $8.00, suggesting a potential upside of 171.19%. Given Lifeward's higher probable upside, analysts clearly believe Lifeward is more favorable than LENSAR.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LENSAR
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

40.2% of LENSAR shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 65.8% of LENSAR shares are held by company insiders. Comparatively, 1.1% of Lifeward shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, LENSAR had 1 more articles in the media than Lifeward. MarketBeat recorded 7 mentions for LENSAR and 6 mentions for Lifeward. LENSAR's average media sentiment score of -0.22 beat Lifeward's score of -0.51 indicating that LENSAR is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
LENSAR
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Lifeward
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Summary

LENSAR beats Lifeward on 12 of the 14 factors compared between the two stocks.

How does Lifeward compare to Precision Optics?

Lifeward (NASDAQ:LFWD) and Precision Optics (NASDAQ:POCI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

In the previous week, Precision Optics had 3 more articles in the media than Lifeward. MarketBeat recorded 9 mentions for Precision Optics and 6 mentions for Lifeward. Precision Optics' average media sentiment score of 0.30 beat Lifeward's score of -0.51 indicating that Precision Optics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lifeward
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative
Precision Optics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 13.7% of Precision Optics shares are owned by institutional investors. 1.1% of Lifeward shares are owned by company insiders. Comparatively, 12.7% of Precision Optics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lifeward currently has a consensus target price of $8.00, suggesting a potential upside of 171.19%. Given Lifeward's stronger consensus rating and higher probable upside, analysts clearly believe Lifeward is more favorable than Precision Optics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lifeward
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Precision Optics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Precision Optics has a net margin of -7.48% compared to Lifeward's net margin of -155.37%. Precision Optics' return on equity of -14.11% beat Lifeward's return on equity.

Company Net Margins Return on Equity Return on Assets
Lifeward-155.37% -295.75% -82.97%
Precision Optics -7.48%-14.11%-8.26%

Lifeward has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Precision Optics has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

Precision Optics has higher revenue and earnings than Lifeward. Precision Optics is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lifeward$22.03M0.38-$19.91M-$15.74N/A
Precision Optics$31.53M1.42-$3.63M-$0.29N/A

Summary

Precision Optics beats Lifeward on 10 of the 15 factors compared between the two stocks.

Get Lifeward News Delivered to You Automatically

Sign up to receive the latest news and ratings for LFWD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LFWD vs. The Competition

MetricLifewardHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$9.08M$5.92B$7.57B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E Ratio-0.1938.8133.9628.21
Price / Sales0.385.308.375.48
Price / CashN/A23.4220.7221.66
Price / Book1.154.154.433.65
Net Income-$19.91M$143.14M$3.51B$394.00M
7 Day Performance-27.34%-4.70%-5.52%-5.64%
1 Month Performance-46.85%-6.70%-8.70%-9.48%
1 Year Performance-52.72%-1.04%-1.43%-6.81%

Lifeward Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LFWD
Lifeward
1.7896 of 5 stars
$2.95
-7.8%
$8.00
+171.2%
-55.2%$9.08M$21.82MN/A81
CNXU
Conexeu Sciences
2.5389 of 5 stars
$2.27
+2.3%
$20.00
+781.1%
N/A$64.04MN/AN/A4
HSAQ
Health Sciences Acquisitions Co. 2
N/A$5.70
+0.4%
N/A+76.4%$63.91MN/AN/A4
RNXT
RenovoRx
3.5118 of 5 stars
$1.22
+3.4%
$8.50
+596.7%
+43.3%$58.87M$1.12MN/A17
LNSR
LENSAR
1.8474 of 5 stars
$4.58
-0.9%
$11.00
+140.2%
-53.8%$56.29M$58.44MN/A150

Related Companies and Tools


This page (NASDAQ:LFWD) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners